ClinicalTrials.gg
CompletedNCT00327418CARDSUpdated May 10, 2007

CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events

A Phase 4 interventional study of Atorvastatin in Major Coronary Event, Cerebrovascular Accident and Coronary Artery Bypass Graft, sponsored by Pfizer. Completed at 135 sites in United Kingdom. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-05-10.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,800
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies testing atorvastatin in Stroke — 4 open to participants now, 4 under way, 2 of them phase 3. Atorvastatin · Stroke.

Enrollment
3rd of 16
2,800 · median 365
Started
1997
the only one that year
Phase 4
7 of 17
1 open now
Registered
3rd of 17
by date
Lead sponsor
2 of 17
Pfizer

Among the 17 studies testing atorvastatin in Stroke, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 1997, is one of 7 in phase 4, and was the 3rd registered.

Stroke

8,277 studies on the registry are indexed under Stroke; 2,067 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 17 studies testing atorvastatin in Stroke are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing atorvastatin in Stroke, or all of them as a file.
02

Study summary

A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.

03

Conditions studied

  • Major Coronary Event
  • Cerebrovascular Accident
  • Coronary Artery Bypass Graft
  • Angina, Unstable
  • Revascularization
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have a documented history of at least one of the following:

  • Hypertension (defined as systolic blood pressure 140 mmHg or a diastolic blood pressure 90 mmHg (defined as the disapperance of all sound [Korotkoff Phase V] or receiving anti-hypertensive treatment. Blood pressure should be measured after sitting the patient quietly for 3 minutes).
  • Retinopathy (defined as any of the following; non-proliferative retinopathy, pre-pre-proliferative retinopathy, proliferative retinopathy, maculopathy, advanced diabetic eye disease or history of photocoagulation).
  • Microalbuminuria (defined as either, Albumin creatinine ratio > than = to 2.5 mg/mmol, or Albumin excretion rate on a timed collection > than = to 20 mcg/min (> than = to 30 mg/24hrs) on two successive occasions, or a positive micral or other strip test).
  • Macroalbuminuria (defined as either; Albustix or other dipstick evidence of gross proteinuria, Albumin creatinine ratio > than = to 25 mg/mmol; or Albumin excretion rate on a timed collection > than = 200 mcg/min (> than = 300 mg/24hrs) on two sucessive occasions).
  • Current smoker

Exclusion criteria

Exclusion Criteria:

  • Type I Diabetes Mellitus
  • Any major Coronary event prior to entry into the study
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
2,800 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Time from randomization to the occurrence of a primary clinical endpoint

  2. i.e. major coronary event or CABG or other coronary revascularization procedure

  3. or unstable angina or resuscitated cardiac arrest or stroke.

Secondary outcomes

  1. The incidence rate of a primary clinical and endpoint; the time from randomization

  2. to the occurrence of and the incidence rate of other parameters e.g. total

  3. mortality, any cardiovascular event, new PVD etc. and the percent change from

  4. baseline in various lipid and lipoprotein parameters.

07

Study locations

135 sites
  • Pfizer Investigational Site
    Fosterhill, Aberdeen AB25 2XG, United Kingdom
  • Pfizer Investigational Site
    Irvine, Ayrshire KA12 0AY, United Kingdom
  • Pfizer Investigational Site
    Midsomer Norton, Bath BA3 2UH, United Kingdom
  • Pfizer Investigational Site
    Reading, Berkshire RG2 7AG, United Kingdom
  • Pfizer Investigational Site
    Slough, Berkshire SL1 2AD, United Kingdom
  • Pfizer Investigational Site
    Maidenhead, Berskhire SL6 6EL, United Kingdom
  • Pfizer Investigational Site
    Edgbaston, Birmingham B15 2TH, United Kingdom
  • Pfizer Investigational Site
    Frenchay, Bristol BS16 1LE, United Kingdom
  • Pfizer Investigational Site
    Llanishen, Cardiff CF14 5GJ, United Kingdom
  • Pfizer Investigational Site
    Wrexham, Clwydd LL13 7TD, United Kingdom
  • Pfizer Investigational Site
    Bocastle, Cornwall PL35 0BG, United Kingdom
  • Pfizer Investigational Site
    Falmouth, Cornwall TR11 2LH, United Kingdom
  • Pfizer Investigational Site
    Fowey, Cornwall PL23 1DT, United Kingdom
  • Pfizer Investigational Site
    Penzance, Cornwall TR18 4JH, United Kingdom
  • Pfizer Investigational Site
    Penzance, Cornwall TR19 7HX, United Kingdom
  • Pfizer Investigational Site
    Redruth, Cornwall TR15 2LL, United Kingdom
  • Pfizer Investigational Site
    Saltash, Cornwall PL12 6DL, United Kingdom
  • Pfizer Investigational Site
    St. Austell, Cornwall PL26 7RL, United Kingdom
  • Pfizer Investigational Site
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Pfizer Investigational Site
    Chesterfield, Derbyshire S40 4TF, United Kingdom
  • Pfizer Investigational Site
    Crownhill, Plymouth, Devon PL5 3JB, United Kingdom
  • Pfizer Investigational Site
    Plymouth, Devon PL6 7TH, United Kingdom
  • Pfizer Investigational Site
    Plympton, Devon PL7 1AD, United Kingdom
  • Pfizer Investigational Site
    Bournemouth, Dorset BH7 7DW, United Kingdom
  • Pfizer Investigational Site
    Bournemouth, Dorset BH8 9EW, United Kingdom
  • Pfizer Investigational Site
    Epping, Essex CM16 6TN, United Kingdom
  • Pfizer Investigational Site
    Southend on Sea, Essex SS1 2AB, United Kingdom
  • Pfizer Investigational Site
    Langside, Glasgow G42 9TY, United Kingdom
  • Pfizer Investigational Site
    Portsmouth, Hampshire PO6 3LY, United Kingdom
  • Pfizer Investigational Site
    Southampton, Hampshire SO31 7DQ, United Kingdom
  • Pfizer Investigational Site
    Titchfield, Hampshire PO14 4EH, United Kingdom
  • Pfizer Investigational Site
    Hemel Hempstead, Hertfordshire HP2 4AD, United Kingdom
  • Pfizer Investigational Site
    Watford, Hertfordshire WD18 0HB, United Kingdom
  • Pfizer Investigational Site
    Ryde, Isle of Wight PO33 2EH, United Kingdom
  • Pfizer Investigational Site
    Gillingham, Kent ME7 5NY, United Kingdom
  • Pfizer Investigational Site
    Hildenborough, Kent TN11 9HL, United Kingdom
  • Pfizer Investigational Site
    Tunbridge Wells, Kent TN1 2DX, United Kingdom
  • Pfizer Investigational Site
    Bolton, Lancashire BL4 0JR, United Kingdom
  • Pfizer Investigational Site
    Ormskirk, Lancashire L39 2AZ, United Kingdom
  • Pfizer Investigational Site
    Waterloo, Liverpool L22 0LG, United Kingdom
  • Pfizer Investigational Site
    Manchester, M15 6sx, United Kingdom
  • Pfizer Investigational Site
    Ashford, Middlesex TW15 2TU, United Kingdom
  • Pfizer Investigational Site
    Southall, Middlesex UB1 3HW, United Kingdom
  • Pfizer Investigational Site
    Scunthorpe, North Lincolnshire DN15 7BH, United Kingdom
  • Pfizer Investigational Site
    Harrogate, North Yorkshire HG2 7SX, United Kingdom
  • Pfizer Investigational Site
    Northallerton, North Yorkshire DL6 1JG, United Kingdom
  • Pfizer Investigational Site
    Sutton-in-Ashfield, Nottinghamshire NG17 4JL, United Kingdom
  • Pfizer Investigational Site
    Worksop, Nottinghamshire S80 1HP, United Kingdom
  • Pfizer Investigational Site
    Huthwaite, Nottingham NG17 2LR, United Kingdom
  • Pfizer Investigational Site
    Headington, Oxford OX3 7LJ, United Kingdom
  • Pfizer Investigational Site
    Haverfordwest, Pembrokeshire SA61 1QX, United Kingdom
  • Pfizer Investigational Site
    Haverfordwest, Pembrokeshire SA61 2PZ, United Kingdom
  • Pfizer Investigational Site
    Shrewsbury, Shropshire SY3 8XG, United Kingdom
  • Pfizer Investigational Site
    Frome, Somerset BA11 1EZ, United Kingdom
  • Pfizer Investigational Site
    Weston-Super-Mare, Somerset BS23 4TQ, United Kingdom
  • Pfizer Investigational Site
    Sheffield, South Yorkshire S5 7HD, United Kingdom
  • Pfizer Investigational Site
    Sheffield, South Yorkshire S5 7QB, United Kingdom
  • Pfizer Investigational Site
    Sheffield, South Yorkshire S7 2DW, United Kingdom
  • Pfizer Investigational Site
    Stirling, Stirlingshire FK8 2AU, United Kingdom
  • Pfizer Investigational Site
    Carshalton, Surrey SM5 1AA, United Kingdom
  • Pfizer Investigational Site
    Epsom, Surrey KT18 7EG, United Kingdom
  • Pfizer Investigational Site
    Pontarddulais, Swansea SA4 1TL, United Kingdom
  • Pfizer Investigational Site
    Dundee, Tayside DD1 9SY, United Kingdom
  • Pfizer Investigational Site
    Dundee, Tayside DD2 5NH, United Kingdom
  • Pfizer Investigational Site
    Hetton le Hole, Tyne & Wear DH5 9EZ, United Kingdom
  • Pfizer Investigational Site
    Gateshead, Tyne and Wear NE9 6SX, United Kingdom
  • Pfizer Investigational Site
    Nuneaton, Warwickshire CV10 7DJ, United Kingdom
  • Pfizer Investigational Site
    Rugby, Warwickshire CV22 5PX, United Kingdom
  • Pfizer Investigational Site
    Lyndon, West Bromwich, West Midlands B71 4HJ, United Kingdom
  • Pfizer Investigational Site
    Livingston, West Lothian EH54 6PP, United Kingdom
  • Pfizer Investigational Site
    Wolverhampton, West Midlands WV10 0QP, United Kingdom
  • Pfizer Investigational Site
    Crawley, West Sussex RH10 1LL, United Kingdom
  • Pfizer Investigational Site
    Crawley, West Sussex RH10 7DX, United Kingdom
  • Pfizer Investigational Site
    Haywards Heath, West Sussex RH16 4EX, United Kingdom
  • Pfizer Investigational Site
    Corsham, Wiltshire SN13 9DL, United Kingdom
  • Pfizer Investigational Site
    Trowbridge, Wiltshire BA14 7EG, United Kingdom
  • Pfizer Investigational Site
    Trowbridge, Wiltshire BA14 9AR, United Kingdom
  • Pfizer Investigational Site
    Warminster, Wiltshire BA14 9AA, United Kingdom
  • Pfizer Investigational Site
    Westbury, Wiltshire BA13 3JD, United Kingdom
  • Pfizer Investigational Site
    York, Yorkshire YO31 8HE, United Kingdom
  • Pfizer Investigational Site
    Ayr, KA6 6DX, United Kingdom
  • Pfizer Investigational Site
    Ayr, KA7 2AA, United Kingdom
  • Pfizer Investigational Site
    Bath, BA1 2SR, United Kingdom
  • Pfizer Investigational Site
    Bath, BA1 3NG, United Kingdom
  • Pfizer Investigational Site
    Bath, BA2 1NH, United Kingdom
  • Pfizer Investigational Site
    Bath, BA2 3HT, United Kingdom
  • Pfizer Investigational Site
    Bath, BA2 4BY, United Kingdom
  • Pfizer Investigational Site
    Belfast, BT12 6BA, United Kingdom
  • Pfizer Investigational Site
    Belfast, BT14 6AB, United Kingdom
  • Pfizer Investigational Site
    Belfast, BT9 7AB, United Kingdom
  • Pfizer Investigational Site
    Birmingham, B15 2SQ, United Kingdom
  • Pfizer Investigational Site
    Birmingham, B37 7TR, United Kingdom
  • Pfizer Investigational Site
    Birmingham, B9 5SS, United Kingdom
  • Pfizer Investigational Site
    Cambridge, CB2 2QQ, United Kingdom
  • Pfizer Investigational Site
    Chippenham, Wiltshire, SN15 2SB, United Kingdom
  • Pfizer Investigational Site
    Co. Dublin, United Kingdom
  • Pfizer Investigational Site
    Coventry, CV1 4FH, United Kingdom
  • Pfizer Investigational Site
    Derby, DE22 3DT, United Kingdom
  • Pfizer Investigational Site
    Dewsbury, WF13 4HS, United Kingdom
  • Pfizer Investigational Site
    Dublin 8, United Kingdom

Showing the first 100 of 135 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA; CARDS Study Investigators. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006 Nov;29(11):2378-84. doi: 10.2337/dc06-0872. PubMed 17065671 ↗
  • Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827. PubMed 31020900 ↗
  • Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004724. doi: 10.1161/CIRCOUTCOMES.118.004724. PubMed 30571333 ↗
  • Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0. PubMed 28573499 ↗
  • Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30. PubMed 27513651 ↗
  • Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt SM, Pressel SL, Davis BR, van der Graaf Y, Visseren FL; CARDS, ALLHAT, and ASCOT Investigators. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):213-21. doi: 10.1161/CIRCOUTCOMES.115.001980. Epub 2016 May 11. PubMed 27174798 ↗
  • Soedamah-Muthu SS, Livingstone SJ, Charlton-Menys V, Betteridge DJ, Hitman GA, Neil HA, Bao W, DeMicco DA, Preston GM, Fuller JH, Stehouwer CD, Schalkwijk CG, Durrington PN, Colhoun HM; CARDS Investigators. Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. Diabetologia. 2015 Jul;58(7):1494-502. doi: 10.1007/s00125-015-3586-8. Epub 2015 Apr 22. PubMed 25899452 ↗
  • Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, Durrington PN, Fuller JH, Livingstone S, Charlton-Menys V, Neil A, Poulter N, Sever P, Shields DC, Stanton AV, Chatterjee A, Hyde C, Calle RA, DeMicco DA, Trompet S, Postmus I, Ford I, Jukema JW, Caulfield M, Hitman GA. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res. 2012 May;53(5):1000-1011. doi: 10.1194/jlr.P021113. Epub 2012 Feb 24. PubMed 22368281 ↗
  • Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21. PubMed 19540640 ↗
  • Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia. 2009 Feb;52(2):218-25. doi: 10.1007/s00125-008-1176-8. Epub 2008 Oct 30. Erratum In: Diabetologia. 2009 Mar;52(3):556. PubMed 18972097 ↗
  • Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Demicco DA, Auster S, Fuller JH; Cards Investigators. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res. 2008 Sep;5(3):177-83. doi: 10.3132/dvdr.2008.029. PubMed 18777490 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1997 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2006
First posted
May 18, 2006
Start
Jan 1997
Completion
Feb 2004
Last update
May 10, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on May 10, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00327418
Lead sponsor
Pfizer
Collaborators
Diabetes UK, Department of Health, United Kingdom
First posted
May 18, 2006
Start date
Jan 1997
Completion
Feb 2004
Last update
May 10, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion